Although initial responses to selective ALK inhibitors are favorable, about 30% of the NPM-ALK+ T cell lymphoma cases develop resistance and have multiple relapses leading to disease-related morbidities and mortalities [17]. The gene discussed is ALK; the disease is T-cell non-Hodgkin lymphoma.